See more : Da Ming International Holdings Limited (1090.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Hepion Pharmaceuticals, Inc. (HEPA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hepion Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Indo Tambangraya Megah Tbk (PTIZF) Income Statement Analysis – Financial Results
- Optima Health plc (OPT.L) Income Statement Analysis – Financial Results
- Xinjiang Machinery Research Institute Co., Ltd. (300159.SZ) Income Statement Analysis – Financial Results
- Keystone Positive Change Investment Trust plc (KPC.L) Income Statement Analysis – Financial Results
- Eni S.p.A. (ENI.BR) Income Statement Analysis – Financial Results
Hepion Pharmaceuticals, Inc. (HEPA)
About Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 67.13K | 77.46K | 86.07K | 34.52K | 26.74K | 18.79K | 21.94K | 0.00 | 21.53K | 16.36K | 0.00 | 0.00 |
| Gross Profit | -67.13K | -77.46K | -86.07K | -34.52K | -26.74K | -18.79K | -21.94K | 0.00 | -21.53K | -16.36K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 35.64M | 33.27M | 20.40M | 12.00M | 3.18M | 7.59M | 14.33M | 13.65M | 15.02M | 8.40M | 314.25K | 734.56K |
| General & Administrative | 9.62M | 10.35M | 10.01M | 8.15M | 4.59M | 7.00M | 7.28M | 7.37M | 5.79M | 5.56M | 1.36M | 106.44K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -583.71K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.62M | 10.35M | 10.01M | 8.15M | 4.59M | 7.00M | 6.69M | 7.37M | 5.79M | 5.56M | 1.36M | 106.44K |
| Other Expenses | 3.19M | 0.00 | 0.00 | 0.00 | -179.65K | -108.94K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.45M | 43.62M | 30.40M | 20.15M | 7.77M | 14.59M | 21.02M | 21.02M | 20.81M | 13.96M | 1.67M | 841.00K |
| Cost & Expenses | 48.45M | 43.62M | 30.40M | 20.15M | 7.77M | 14.59M | 21.04M | 21.02M | 20.81M | 13.96M | 1.67M | 841.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 9.47K | 10.16K | 8.86K | 31.23K | 555.00K | 339.16K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 67.13K | 77.46K | 86.07K | 34.52K | 26.74K | 18.79K | 21.94K | 27.99K | 21.53K | 16.36K | 1.32K | 841.00K |
| EBITDA | -49.26M | -43.54M | -30.32M | -20.11M | -7.74M | -14.58M | -20.62M | -21.02M | -20.81M | -13.94M | -1.67M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -48.45M | -45.49M | -30.40M | -20.15M | -7.77M | -14.59M | -21.04M | -21.02M | -20.81M | -13.96M | -1.67M | -841.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -887.11K | 404.83K | -2.32M | -177.28K | -175.94K | 4.61M | 2.13M | 4.22M | 3.81M | -387.90K | -3.61M | -1.97K |
| Income Before Tax | -49.34M | -45.08M | -32.72M | -20.32M | -7.95M | -9.99M | -18.92M | -16.80M | -17.00M | -14.35M | -5.28M | -842.97K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 409.02K | -2.88M | 8.86K | 30.58K | -908.68K | -536.00K | -3.90M | -1.91M | -3.81M | 387.90K | 3.61M | -1.97K |
| Net Income | -48.93M | -42.20M | -32.72M | -20.35M | -7.04M | -9.45M | -15.02M | -14.89M | -17.00M | -14.35M | -5.28M | -842.97K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -12.32 | -11.07 | -9.31 | -42.06 | -68.88 | -1.03K | -2.17K | -2.86K | -7.04K | -7.39K | -4.62K | -25.55 |
| EPS Diluted | -12.32 | -11.07 | -9.31 | -42.06 | -68.88 | -1.03K | -2.17K | -2.86K | -7.04K | -7.39K | -4.62K | -25.55 |
| Weighted Avg Shares Out | 3.97M | 3.81M | 3.51M | 483.89K | 102.16K | 9.19K | 6.91K | 5.20K | 2.42K | 1.94K | 1.14K | 33.00K |
| Weighted Avg Shares Out (Dil) | 3.97M | 3.81M | 3.51M | 483.89K | 102.16K | 9.19K | 6.91K | 5.21K | 2.42K | 1.94K | 1.14K | 33.00K |
Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study Group
KIRYAT ONO, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Pharma Two B , a private, late-stage pharmaceutical company developing innovative combination drugs for neurological disorders, today announced a poster presentation of integrated safety and efficacy data on P2B001 from its...
Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Transaction Creates Opportunity to Share in Potential Upside of Pharma Two B's Late-Clinical Stage Candidate to Treat Parkinson's Disease
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
KIRYAT ONO, ISRAEL and EDISON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the treatment of Parkinson's Disease (“PD”) and...
Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer
Monday, Hepion Pharmaceuticals Inc (NASDAQ: HEPA) entered into a definitive merger agreement with Pharma Two B Ltd., a late-clinical stage private Israeli company developing P2B001, a combination product candidate in development for Parkinson's Disease.
Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?
Hepion Pharmaceuticals (NASDAQ: HEPA ) stock is diving on Monday after the biopharmaceutical company announced plans to wind down a clinical trial. A press release from the company notes that it is winding down it Phase 2b ASCEND-NASH study.
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH' Trial
EDISON, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it has...
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, and other chronic diseases, today announced the appointment of...
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic...
Hepion Pharmaceuticals to Present at NASH-TAG 2024
EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic...
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
Restructuring program purpose is to preserve capital and optimize clinical development program Management plans to continue to evaluate its Phase 2b ASCEND-NASH clinical trial taking in account current market environment Cash runway extended into Q2 2025 EDISON, N.J., Dec. 07,...
Source: https://incomestatements.info
Category: Stock Reports